Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

NCT04983030 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

HIV
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndrome, Acquired
Sexually Transmitted Diseases, Viral
Retroviridae Infections

Interventions

BIOLOGICAL: Ad26.Mos4.HIV
BIOLOGICAL: MVA-BN-HIV
BIOLOGICAL: PGT121
BIOLOGICAL: PGDM1400
BIOLOGICAL: VRC07-523LS

Sponsor

Boris Juelg, MD PhD

Collaborators

[object Object]
[object Object]
[object Object]